What a Peptide Certificate of Analysis Does Not Test For

Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.

A certificate of analysis is a list of the tests a laboratory ran on a sample from one lot, and nothing else. This article maps the blind spots of a standard research-peptide panel: stereochemistry, aggregation, biological activity, counter-ion, container compatibility, storage history and sampling limits. Knowing what a certificate does not say is the only way to read what it does say correctly.

What a standard panel covers, and what sits outside it

A standard research-peptide certificate reports identity by mass spectrometry, purity by reversed-phase HPLC, net peptide content, bacterial endotoxin, sterility and heavy metals, each on a sample drawn from the lot on a stated date. Those tests answer six questions well. They do not answer whether every residue has the right stereochemistry, whether the peptide is monomeric in solution, whether it is biologically active, how much of the mass is counter-ion, whether it will stick to your tubes, or what has happened to the vial since the test date.

The gap is structural rather than a matter of vendor effort. Each of the six standard tests is a validated procedure in the sense of USP General Chapter <1225>, which defines analytical categories (major-component assay, impurity determination, performance characteristics, identification) and the parameters each must meet: accuracy, precision, specificity, detection and quantitation limits, linearity, range and robustness. A procedure validated for one category says nothing about another. An HPLC purity method validated for related impurities is not a test of aggregation, and an intact-mass identity test is not a test of chirality.

Stereochemistry

An intact-mass identity test cannot tell a D-amino acid from an L-amino acid, because an epimer has exactly the same molecular formula and mass as the correct peptide. Solid-phase synthesis racemizes certain residues at a low rate, histidine and cysteine most readily, during activation and coupling, and the resulting diastereomers often co-elute with the main peak in reversed-phase HPLC or separate only partially. D'Hondt and colleagues listed epimers among the related impurities of synthetic peptides in a 2014 Journal of Pharmaceutical and Biomedical Analysis review, alongside deletion sequences, deamidation products and oxidation products.

Detecting an epimer requires a chiral method. The classical route is acid hydrolysis followed by chiral gas or liquid chromatography of the derivatized amino acids, which reports the D-content of each residue type but not its position. Jia, Lietz, Yu and Li described a position-specific alternative in a 2014 Analytical Chemistry paper, using ion-mobility spectrometry of fragment ions to localize a D-residue in melanocyte-stimulating hormone and deltorphin epimers. Neither method is part of a routine research certificate. Where stereochemistry matters to an experiment, it has to be requested as an additional test. Our article on LC-MS identity confirmation covers the full list of what a mass spectrum cannot distinguish.

Aggregation and higher-order structure

The HPLC purity method runs in acetonitrile and 0.1 percent trifluoroacetic acid, conditions that dissolve most non-covalent aggregates into monomers before they reach the column. A lot can therefore report 99 percent purity and still contain peptide that, once reconstituted in a neutral aqueous buffer, assembles into dimers, oligomers or fibrils. Zapadka, Becher, Gomes Dos Santos and Jackson reviewed the factors that drive peptide aggregation in a 2017 Interface Focus article: sequence hydrophobicity, net charge near the isoelectric point, concentration, temperature, agitation, and interfaces such as air-water and container walls. Mahler, Friess, Grauschopf and Kiese catalogued the pathways and the analytical methods for detecting aggregates in a 2009 Journal of Pharmaceutical Sciences review.

Chemical changes feed physical ones. Nilsson, Driscoll and Raleigh showed in a 2002 Protein Science paper that as little as 5 percent deamidated material, an asparagine converted to aspartate or isoaspartate, dramatically accelerated fibril formation of an amyloidogenic peptide, meaning a minor impurity on the HPLC trace can set the aggregation behavior of the whole sample. The methods that see aggregates, size-exclusion chromatography, dynamic light scattering, analytical ultracentrifugation and thioflavin-T fluorescence, are not on a standard research certificate. The acylated GLP-1-class peptides, which are designed to self-associate and to bind albumin, are the most relevant example.

Biological activity and counter-ion content

A standard research certificate contains no measure of biological activity. Identity, purity and content are chemical quantities; whether the molecule binds its receptor or produces a cellular response is a separate question answered only by a bioassay, and research-grade certificates almost never include one. A peptide can be chemically correct and biologically inactive, for instance if a critical cysteine pair has formed the wrong disulfide bridge (same mass, different connectivity) or if a position-specific epimer sits at a receptor-contact residue. The article Purity Is Not Potency covers these three measurements separately.

Counter-ion content is the second omission, and a quieter one. Most synthetic peptides are trifluoroacetate salts, with 10 to 45 percent of the powder mass as counter-ion depending on the number of basic residues. A certificate that lists HPLC purity but neither a counter-ion figure nor a net peptide content line leaves the researcher unable to calculate how much peptide a weighed mass contains. The counter-ion itself can also affect cell assays at nanomolar levels, as reviewed in TFA Salt vs Acetate Salt. Melanson and colleagues at the National Research Council of Canada showed in a 2018 Analytical and Bioanalytical Chemistry paper how a metrological purity assignment combines quantitative NMR and amino-acid analysis to account for water, counter-ion and peptide impurities together; that level of mass balance is the exception, not the norm, on a commercial certificate.

Container, adsorption and storage history

A certificate describes a sample at the time of testing and says nothing about the container it will be handled in afterward or the conditions it has been kept under since. Both change what is actually available in a vial. Goebel-Stengel, Stengel, Taché and Reeve measured the recovery of eight radiolabeled peptides, including GLP-1, ghrelin, insulin and peptide YY, from glass and plastic tubes over 48 hours in a 2011 Analytical Biochemistry paper. Recovery varied widely by peptide and surface, siliconized surfaces reduced it, adding 1 percent bovine serum albumin improved it, and the authors concluded that container choice must be tested for each peptide to avoid unpredictable loss and false conclusions. No certificate can predict that loss, because it depends on the researcher's labware, buffer and concentration.

Storage history is the other invisible variable. Wang's 2000 International Journal of Pharmaceutics review of lyophilization explains why residual moisture in a freeze-dried cake governs its long-term stability, and Manning, Chou, Murphy, Payne and Katayama's 2010 Pharmaceutical Research update lists the chemical degradation routes that proceed in the solid and in solution: deamidation, oxidation of methionine and cysteine, hydrolysis at aspartate, disulfide scrambling and racemization. All of them are functions of temperature, moisture, light and time after the test date. The certificate's issue date is therefore a boundary: the numbers describe the lot on that day, under the laboratory's conditions. What a vial contains after a summer in a delivery van or a year in a frost-free freezer is a question for the receiving laboratory's own log.

Sampling and method limits

Every number on a certificate is a measurement of a sample, with a detection limit, and both facts limit what it can claim. Sterility and endotoxin tests are run on a small number of units from the lot, so they are statements about the lot's probability of contamination, not a guarantee about the unit in hand. HPLC impurity reporting has a threshold, often 0.05 to 0.1 percent of the main peak, below which peaks are not listed, and a UV detector only sees components that absorb at the chosen wavelength, so non-chromophoric contaminants are invisible to it. The FDA's 2017 Federal Register notice on synthetic peptide drug products framed the regulatory version of this concern, calling for peptide-related impurities to be characterized by methods able to resolve them; the same logic applies to reading any research certificate.

Two limits deserve particular attention. First, an area-percent purity figure assumes every impurity absorbs UV as strongly as the main peptide, which is not true of deletion sequences that have lost an aromatic residue; the companion article on HPLC area percent explains the response-factor problem. Second, an identity test confirms that the main peak has the right mass; it does not confirm that minor peaks are what the certificate assumes they are.

What a laboratory can do with the gaps

The gaps in a certificate are closed by the receiving laboratory, not by a better certificate. The practical steps are short. Ask the vendor for the raw chromatogram and mass spectrum rather than the summary line, so that peak shapes, minor peaks and the charge-state series can be checked. For any experiment where stereochemistry, aggregation state or activity matters, run the orthogonal test yourself or commission it: a size-exclusion run, a chiral amino-acid analysis, or a receptor assay in your own cell system. Record arrival condition, storage temperature and each reconstitution in the lab notebook so that the vial's history after the test date is known.

US Prime Peptides posts a lot-matched certificate on each product page before purchase, listing identity by mass spectrometry, HPLC purity, net peptide content, endotoxin, sterility and heavy metals, and will supply the underlying data on request. That is what a certificate can honestly deliver. The questions in this article are the ones it cannot, and the research design should account for them rather than assume they have been answered.

Frequently Asked Questions

What does a peptide certificate of analysis not test for?

A standard panel does not test stereochemistry (D- versus L-residues), aggregation state, biological activity, container adsorption, or anything that has happened to the vial after the test date. Counter-ion content is reported by some laboratories and omitted by others. Each of these needs a separate, specialized method.

Can a COA show 99% purity and still have the wrong stereochemistry?

Yes. An epimer with a D-amino acid at one position has the same mass as the correct peptide and often the same HPLC retention time, so it passes both the identity and purity tests. Only chiral amino acid analysis or an ion-mobility method such as the one Jia and colleagues described in 2014 can detect it.

Does a certificate of analysis tell you if a peptide is biologically active?

No. Research-grade certificates report chemical measurements, identity, purity and content, and almost never include a receptor-binding or cell-based activity assay. A peptide can be chemically correct and still inactive, for example because of disulfide mis-pairing or an epimer at a receptor-contact residue.

Is the COA still valid after the peptide has been stored for a year?

The certificate remains an accurate record of the lot on the test date, but it does not describe the vial after storage. Deamidation, oxidation, moisture uptake and aggregation all proceed with time, temperature and humidity, so a laboratory that needs current values after long storage should re-test rather than rely on the original report.

Citations

1. D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. PMID 25044089
2. Jia C, Lietz CB, Yu Q, Li L. Site-specific characterization of (D)-amino acid containing peptide epimers by ion mobility spectrometry. Anal Chem. 2014;86:2972-2981. PMID 24328107
3. Zapadka KL, Becher FJ, Gomes Dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017;7:20170030. PMID 29147559
4. Mahler HC, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci. 2009;98:2909-2934. PMID 18823031
5. Nilsson MR, Driscoll M, Raleigh DP. Low levels of asparagine deamidation can have a dramatic effect on aggregation of amyloidogenic peptides: implications for the study of amyloid formation. Protein Sci. 2002;11:342-349. PMID 11790844
6. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414:38-46. PMID 21315060
7. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203:1-60. PMID 10967427
8. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27:544-575. PMID 20143256
9. Melanson JE, Thibeault MP, Stocks BB, Leek DM, McRae G, Meija J. Purity assignment for peptide certified reference materials by combining qNMR and LC-MS/MS amino acid analysis results: application to angiotensin II. Anal Bioanal Chem. 2018;410:6719-6731. PMID 30143839
10. United States Pharmacopeia. General Chapter <1225> Validation of Compendial Procedures. USP 35-NF 30. archived chapter text
11. FDA. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin; Draft Guidance for Industry; Availability. Federal Register. 2017;82:46057. govinfo.gov

This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.

Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.